Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b Extension Trial of RB-ADSC in Alzheimer's Disease
NCT07373067Phase 1Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Modality
- Mesenchymal Stem Cells, Patient-derived iPSCs, Allogeneic iPSCs
01
Overview
Phase 1, open-label trial of astrostem in Alzheimer's disease (AD) (3 arms). Primary endpoint: Safety of repeated RB-ADSC treatment at 12 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
astrostem
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07373067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07373067.